Efficacy and safety of bevacizumab combined with capecitabine in the treatment of advanced breast cancer

Abstract

Abstract:

ObjectiveTo investigate the efficacy and safety of bevacizumab combined with capecitabine in the treatment of advanced breast cancer.MethodsSeventy-six patients with advanced breast cancer who were diagnosed in the Cancer Center of the People's Liberation Army Navy Anqing Hospital from August 2019 to May 2021 were selected. According to different treatment schemes， the patients were divided into the control group （using single drug capecitabine） and the test group （using bevacizumab combined with capecitabine）， with 38 cases in each group. After 4 cycles of treatment， the clinical efficacy， progression-free survival （PFS）， overall survival （OS） and adverse reactions were compared between the two groups， and the levels of vascular endothelial growth factor （VEGF）-121， VEGF-145， VEGF-165 and quality of life before and after treatment were compared.ResultsThe objective remission rate of the test group [57.89% （22/38）] was higher than that of the control group [42.11% （16/38）]， but there was no statistically significant difference （χ²=1.89，P=0.169）； The disease control rate of the test group [81.58% （31/38）] was better than that of the control group [55.26% （21/38）]， there was a statistically significant difference （χ²=6.09，P=0.014）. The median PFS of patients in the test group （6.3 months） was longer than that in the control group （4.2 months）， there was a statistically significant difference （χ²=0.48，P=0.003）； The median OS of patients in the test group （14.8 months） was not significantly different from that in the control group （13.2 months）（χ²=0.15，P=0.704）. After treatment， the expression level of serum VEGF-121 [（201.25±18.37） ng/Lvs.（276.83±20.26） ng/L]， VEGF-145 [（102.24±12.16） ng/Lvs.（170.39±15.28） ng/L]， VEGF-165 [（135.08±14.32） ng/Lvs.（210.53±16.09） ng/L] in the test group was lower than that in the control group， there were statistically significant differences （t=17.03，P<0.001；t=21.51，P<0.001；t=21.59，P<0.001）. After treatment， patients in the test group were assessed according to 36-item Short-Form （SF-36） physiological function [（80.18±13.96） scorevs.（71.72±16.12） score]， physiological function [（67.19±30.62） scorevs.（53.12±9.86） score]， physical pain [（70.01±17.97） scorevs.（61.06±17.57） score]， overall health [（68.67±18.92） scorevs.（57.96±20.97） score]， vitality [（78.39±19.37） scorevs.（68.26±18.52） score]， social function [（82.24±19.73） scorevs.（70.92±20.31） score]， the scores of emotional function [（73.81±28.86） scorevs.（60.23±29.19） score] and mental health [（76.19±12.82） scorevs.（70.31±12.54） score] were higher than those of the control group， there were statistically significant differences （t=2.45，P=0.017；t=2.03，P=0.046；t=2.19，P=0.031；t=2.34，P=0.022；t=2.33，P=0.023；t=2.46，P=0.016；t=2.04，P=0.045；t=2.02，P=0.047）. The incidence of adverse reactions in the test group [18.42% （7/38）] was lower than that in the control group [76.32% （29/38）]， there was a statistically significant difference （χ²=25.54，P<0.001）.ConclusionThe combination of bevacizumab and capecitabine chemotherapy has a higher clinical effect on advanced breast cancer， which can significantly reduce the level of VEGF in patients， improve the quality of life of patients， with mild adverse reactions and high safety.

Key words:Breast neoplasms,Treatment outcome,Drug-related side effects and adverse reactions,Bevaczumab,Kapitabin

Zhou Ting, Xu Shaohua, Mei Lin. Efficacy and safety of bevacizumab combined with capecitabine in the treatment of advanced breast cancer[J]. Journal of International Oncology, 2023, 50(3): 144-149.

Figures/Tables7

临床特征	试验组（n=38）	对照组（n=38）	t/χ²/Z值	P值
年龄（岁）	59.37±11.28	60.15±12.08	0.29	0.772
转移情况
单个部位	16（42.11）	19（50.00）	0.48	0.490
两个及以上	22（57.89）	19（50.00）
肿瘤分期
Ⅱ期	5（10.53）	4（40.53）
Ⅲ期	28（73.68）	26（68.42）	0.13	0.723
Ⅳ期	5（10.53）	8（21.05）

组别	CR	PR	SD	PD	客观缓解	疾病控制
试验组（n=38）	12（31.58）	10（26.32）	9（23.38）	7（18.42）	22（57.89）	31（81.58）
对照组（n=38）	7（18.42）	9（23.38）	5（13.16）	17（44.74）	16（42.11）	21（55.26）
χ²值					1.89	6.09
P值					0.169	0.014

组别	VEGF-121			VEGF-165
试验组（n=38）	325.16±22.92	201.25±18.37^a	223.07±19.14	102.24±12.16^a	263.95±18.86	135.08±14.32^a
对照组（n=38）	323.05±22.18	276.83±20.26^a	221.64±18.36	170.39±15.28^a	265.16±19.58	210.53±16.09^a
t值	0.41	17.03	0.33	21.51	0.27	21.59
P值	0.685	<0.001	0.741	<0.001	0.785	<0.001

组别	生理功能		生理职能		躯体疼痛		总体健康
组别	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
试验组（n=38）	58.25±18.34	80.18±13.96^a	42.25±7.63	67.19±30.62^a	55.85±20.34	70.01±17.97^a	41.12±5.83	68.67±18.92^a
对照组（n=38）	58.62±17.98	71.72±16.12^a	39.32±4.65	53.12±9.86^a	55.38±20.51	61.06±17.57^a	40.96±6.39	57.96±20.97^a
t值	0.09	2.45	0.49	2.03	0.10	2.19	0.03	2.34
P值	0.929	0.017	0.624	0.046	0.920	0.031	0.974	0.022
组别	活力		社会功能		情感职能		精神健康
组别	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
试验组（n=38）	53.91±18.39	78.39±19.37^a	61.59±21.08	82.24±19.73^a	39.96±3.94	73.81±28.86^a	59.57±13.99	76.19±12.82^a
对照组（n=38）	54.18±19.18	68.26±18.52^a	61.37±20.83	70.92±20.31^a	40.18±6.67	60.23±29.19^a	59.42±14.08	70.31±12.54^a
t值	0.06	2.33	0.05	2.46	0.12	2.04	0.05	2.02
P值	0.950	0.023	0.964	0.016	0.906	0.045	0.963	0.047

组别	胸闷	高血压	恶心	发热	呕吐、腹泻	合计
试验组（n=38）	2（5.26）	0（0）	3（7.89）	1（2.63）	1（2.63）	7（18.42）
对照组（n=38）	8（21.05）	3（7.89）	10（26.32）	3（7.89）	5（13.16）	29（76.32）
χ²值						25.54
P值						<0.001

References15

[1]	张雪, 董晓平, 管雅喆, 等. 女性乳腺癌流行病学趋势及危险因素研究进展[J]. 肿瘤防治研究, 2021, 48(1): 87-92.
[2]	陈曦. 乳腺癌更新治疗“指南针”——专家解读《2019CSCO乳腺癌诊疗指南》[J]. 家庭医学(下半月), 2019(5): 49.
[3]	Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer[J]. N Engl J Med, 2007, 357(26): 2666-2676. DOI: 10.1056/NEJMoa072113. doi:10.1056/NEJMoa072113
[4]	Meriggi F, Abeni C, Di Biasi B, et al. The use of bevacizumab and trastuzumab beyond tumor progression: a new avenue in cancer treatment?[J]. Rev Recent Clin Trials, 2009, 4(3): 163-167. DOI: 10.2174/157488709789957682. doi:10.2174/157488709789957682pmid:20028327
[5]	Valachis A, Polyzos NP, Patsopoulos NA, et al. Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials[J]. Breast Cancer Res Treat, 2010, 122(1): 1-7. DOI: 10.1007/s10549-009-0727-0. doi:10.1007/s10549-009-0727-0
[6]	Park SO, Yoo YB, Kim YH, et al. Effects of combination therapy of docetaxel with selenium on the human breast cancer cell lines MDA-MB-231 and MCF-7[J]. Ann Surg Treat Res, 2015, 88(2): 55-62. DOI: 10.4174/astr.2015.88.2.55. doi:10.4174/astr.2015.88.2.55pmid:25692115
[7]	皋文君, 刘砚燕, 袁长蓉. 国际肿瘤化疗药物不良反应评价系统——通用不良反应术语标准4.0版[J]. 肿瘤, 2012, 32(2): 142-144.
[8]	Ricciuti B, Awad MM. Atezolizumab plus bevacizumab in TMB-high non-small cell lung cancers—the hunt for predictive biomarkers to optimize treatment selection[J/OL]. JAMA Oncol. [2022-12-15]. https://jamanetwork.com/journals/jamaoncology/article-abstract/2799495. DOI: 10.1001/jamaoncol.2022.5801. doi:10.1001/jamaoncol.2022.5801
[9]	韦惠章, 潘嘉问, 薛协持, 等. 贝伐珠单抗联合热灌注化疗方案治疗晚期卵巢癌的近远期效果及其对VEGF、HDGF和MIF表达水平的影响[J]. 中国医药导报, 2016, 13(8): 25-28.
[10]	李源丰, 林观毛, 刘琼荣, 等. 促性腺激素释放激素激动剂辅助长春瑞滨+卡培他滨化疗方案在青年乳腺癌患者中的应用价值[J]. 中国药物经济学, 2020, 15(11): 122-124, 128. DOI: 10.12010/j.issn.1673-5846.2020.11.032. doi:10.12010/j.issn.1673-5846.2020.11.032
[11]	罗的的. 观察贝伐珠单抗注射液联合新辅助化疗治疗乳腺癌的临床疗效及安全性[J]. 当代医学, 2021, 27(26): 38-40. DOI: 10.3969/j.issn.1009-4393.2021.26.015. doi:10.3969/j.issn.1009-4393.2021.26.015
[12]	乔雪, 李士猛, 杨红梅. 紫杉醇或吉西他滨联合顺铂治疗蒽环类耐药晚期乳腺癌患者临床疗效及安全性观察[J]. 中国肿瘤临床与康复, 2019, 26(12): 1478-1481. DOI: 10.13455/j.cnki.cjcor.2019.12.18. doi:10.13455/j.cnki.cjcor.2019.12.18
[13]	徐晓敏, 董琳, 崔金芳, 等. 多西紫杉醇联合卡铂或卡培他滨一线治疗乳腺癌肺转移的疗效对比[J]. 现代肿瘤医学, 2020, 28(23): 4088-4092. DOI: 10.3969/j.issn.1672-4992.2020.23.015. doi:10.3969/j.issn.1672-4992.2020.23.015
[14]	王月, 李蕾蕾, 朱琳琳. 贝伐珠单抗联合化疗治疗转移性结直肠癌对患者血清VEGF和TAP水平的影响[J]. 临床和实验医学杂志, 2022, 21(9): 959-963. DOI: 10.3969/j.issn.1671-4695.2022.09.017. doi:10.3969/j.issn.1671-4695.2022.09.017
[15]	段海波, 胡倩, 林颖欣, 等. 曲妥珠单抗联合拉帕替尼及多西紫杉醇一线治疗HER-2阳性晚期乳腺癌的安全性和有效性[J]. 现代肿瘤医学, 2020, 28(18): 3159-3163. DOI: 10.3969/j.issn.1672-4992.2020.18.013. doi:10.3969/j.issn.1672-4992.2020.18.013